Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Interventional × Adrenal Insufficiency × Clear all

Phase

Status

Unknown 2 Recruiting 1 Completed 1

Sponsor Class

Study Type

Observational 2 Interventional 1

Sponsor

Conditions

Breast Neoplasms 1327 Neoplasms 1007 Carcinoma, Non-Small-Cell Lung 853 Prostatic Neoplasms 723 Colorectal Neoplasms 664 Lung Neoplasms 547 Leukemia, Myeloid, Acute 467 Neoplasm Metastasis 427 Pancreatic Neoplasms 421 Carcinoma, Hepatocellular 405 Multiple Myeloma 389 Ovarian Neoplasms 386 Stomach Neoplasms 371 Recurrence 362 Squamous Cell Carcinoma of Head and Neck 316 Melanoma 292 Uterine Cervical Neoplasms 288 Brain Neoplasms 275 Triple Negative Breast Neoplasms 266 Head and Neck Neoplasms 257 Glioblastoma 256 Precursor Cell Lymphoblastic Leukemia-Lymphoma 255 Endometrial Neoplasms 238 Lymphoma 231 Esophageal Neoplasms 228 Sarcoma 219 Rectal Neoplasms 219 Carcinoma, Renal Cell 201 Colonic Neoplasms 198 Lymphoma, Large B-Cell, Diffuse 191

Interventions

ravulizumab 1 Prednisone 1 Prednisolone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07221838 2026-04-09

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Recruiting

Adrenal Insufficiency, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡